 •		40	*		*			-	*								_	-	·	⊏	v
 ~	;-=	٠.	۸.	۰,		-74	-4	٠,	•	-	1	Ð	ياريا	1	Ŀ	Ŀ	7			_	-

HM12/1210

FLEHR HOHBACH TEST ALBRITTON & HERBERT SUITE 3400 FOUR EMBARCADERO STREET SAN FRANCISCO CA 94111

EXAM	NER
SAOUD,	6
ART UNIT	PAPER NUMBER
1646	19
DATE MAILED:	12/10/99

Below is a communication from the EXAMINER in charge of this application

COMMISSIONER OF PATENTS AND TRADEMARKS

ADVISORY ACTION

THE PERIOD !	OR RESPONSE:
-> =	to run or continues to run from the date of the final rejection
h) [avaires th	ee months from the date of the final rejection or as or the maning date of the final rejection.
Any exter The date purposes	sion of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and the appropriate reconstruction of time must be obtained by filing a petition under 37 CFR 1.136(a), the proposed response and also the date for the point which the response, the petition and the fee have been filed is the date of the response and also the date for the point of the fee. Any extension fee pursuant to 37 CFR of determining the period of extension and the corresponding amount of the fee. Any extension fee pursuant to 37 CFR of the priginally set shortened statutory period for response or as set forth in b) above.
Appellant's B	rief is due in accordance with 37 CFR 1.192(a). sponse to the final rejection, filed 29 Nov 155 has been considered with the following effect, but it is not deemed application in condition for allowance:
Applicant's re	sponse to the final rejection for allowance: upplication in condition for allowance:
1. The prop	application in condition for allowance. Does discontinuous and for specification will not be entered and the final rejection stands because: Does discontinuous and for specification will not be entered and the final rejection stands because: Does discontinuous and was not earlier Does discontinuous and was not earlier Does discontinuous and was not earlier
a. 🔲 Th pr	ere is no convincing showing under 37 OTT 111 (4.7) assented. (See Note).
	esented. ey raise new issues that would require further consideration and/or search. (See Note).
c. 🔲 T	ney raise the issue of new matter. (See Note). hey are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for
d. 🔲 T	ney are not deemed to place the application at the property of finally rejected claims.
e. 🔲 1	ppeal. hey present additional claims without cancelling a corresponding number of finally rejected claims.
NOTE:	
2 □ Newly	proposed or amended claims would be allowed if submitted in a separately filed amendment cancelling
the no	proposed of animosos. n-allowable claims. will be entered will not be entered and the status of the claims will will not be entered and the status of the claims will the filing an appeal, the proposed amendment will be entered
3. Upon be as	follows:
Claim	s allowed: s objected to:
Claim	s objected to:
Clain	s rejected:
	However; Applicant's response has overcome the following rejection(s):
	affidavit, exhibit or request for reconsideration has been considered but does not overcome the rejection because
4. The	affidavit, exhibit of request at the discount of the second secon
nro	affidavit or exhibit will not be considered because applicant has not shown good and sufficent reasons why it was not earlier sented.
The proj	posed drawing correction has has not been approved by the examiner.
Other	- Best Steel a server

Advisory action - Paper No. 19

Serial No. 08/734,443

Applicant urges that Pötgens cannot anticipate the present claims because it teaches that none of the mutants examined inhibited native VEGF. A careful reading of the reference reveals that what Pötgens in fact teaches is that its mutants did not inhibit wild-type VEGF in a mitotic assay.

Applicant's argument would be persuasive if the claims required inhibition of mitotic activity. What the claims do require, however, is that the claimed mutant "be capable of inhibiting a biological activity of a native VEGF protein." This limitation would be met by a mutant which inhibits *any* biological activity of *any* native VEGF. Such activity could be, for example, the ability of native VEGF to compete for binding to the same receptor in a given biological system. *See* the specification at 10, paragraph bridging to 11. Indeed, Fig. 6 of the Pötgens reference demonstrates that the several mutants do in fact compete with native VEGF for binding to its receptor. The evidence of record suggests that because the prior art mutants differ in structure and qualitative biological properties from at least one native VEGF, they are more likely than not to inherently possess functional attributes which meet the broadest reasonable construction of the claims.

Examiner Saoud is on leave until February of 2000. In the interim, any inquiry concerning this communication should be directed to David Fitzgerald at telephone number (703) 308-3934 or fax number (703) 308-0294. Inquiries of a general nature should be directed to the Technology Center 1600 receptionists at (703) 308-0196.

DAVID L. FITZGERALD

PRIMARY EXAMINER

ART UNIT 1646

25

5

10

15

20

9 December 1999